Drug Primer

Veozah acts as a neurokinin 3 (NK3) receptor antagonist, which inhibits the binding of neurokinin B to kisspeptin/neurokinin B/dynorphin neurons.

In December 2021, the US Food and Drug Administration (FDA) approved upadacitinib (Rinvoq® [AbbVie, Inc.]), a Janus kinase (JAK) inhibitor, for the treatment of adults with active psoriatic arthritis with an inadequate response or who demonstrate intolerance to at least 1 tumor necrosis factor (TNF) blocker.  Upadacitinib acts by inhibiting intracellular JAK enzymes, which transmit…